Developing a New Class of Autoimmune Drugs
Breakthrough Developments in Live Microbial Biotherapeutics
Redefining Microbiome Research

Australian biopharmaceutical research

View Our Work Latest News

Welcome to Servatus

We are an Australian biopharmaceutical company, focused on drug development platforms and the production of medical grade biopharmaceuticals.  We will deliver first-line and adjunct treatments for select autoimmune, gastrointestinal and dermatological conditions.

  • Our primary platform is engineering recombinant proteins to improve their clinical utility for the effective treatment of autoimmune diseases and inflammatory conditions.
  • Our secondary drug development platform include the isolation, characterisation and engineering of select live biotherapeutics for the treatment of microbiome-associated conditions. Initial investigations have delivered exceptional results in one of the most exciting areas of global drug development.
  • Via a recently announced joint venture, we will commence production of medical grade biopharmaceuticals in a soon to be constructed, state-of-the-art facility in the state of Queensland, Australia.

Learn more about us

Novel Treatments for autoimmune Disease

safe and effective treatments

There is a clear need to develop safe and effective treatments for immune-mediated inflammatory diseases. Our research is directed at improving specific characteristics of select proteins for autoimmune conditions. We are targeting key features of the protein to improve its clinical efficacy and to complement existing drug therapies.

  • Harnessing new modes of action provides the greatest opportunity to advance medical therapies for the future, as drugs currently available reach their limit in providing long-term efficacy and safety for patients.
  • Servatus has to date, engineered a modified protein selected on its natural inherent immune modulating ability, with anticipated improvements both in clinical efficacy and commercial delivery.
     

Autoimmune Research

Unlocking the potential of the microbiome will reshape disease treatment

Live microbial biotherapeutic agents

We have isolated and characterised select microbial species and undertaken extensive pre-clinical investigations to develop highly defined medicines, addressing inflammatory and autoimmune conditions.

Human clinical trials will confirm the clinical utility of these medicines, with the aim to advance safe and effective treatments.

At Servatus one of our key projects is the development of pharmaceutical grade live microbial biotherapeutic agents, derived from microorganisms predominantly of bacterial origin.

  • We have isolated and characterised select microbial species and we are currently undertaking extensive pre-clinical investigations to develop highly defined medicines, addressing inflammatory and autoimmune conditions.
  • Upcoming human clinical trials will confirm the clinical utility of these medicines, with the aim to advance safe and effective treatments.

live microbial biotherapeutic research